Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 3/20 | 0.37 |
| ▸ | F11 | P03951 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13395119 | 1.00 | F10 (0.40) | F10LMNAMAPK1KMT2AF2 | |
| SCHEMBL13395115 | 0.91 | F10 (0.42) | F10LMNAMAPK1KMT2AF2 | |
| SCHEMBL3306290 | 0.91 | F10 (0.42) | F10LMNAMAPK1KMT2AF2 | |
| SCHEMBL13395099 | 0.89 | F10 (0.43) | F10LMNAMAPK1KMT2AF2 | |
| SCHEMBL3308325 | 0.89 | F10 (0.43) | F10LMNAMAPK1KMT2AF2 | |
| SCHEMBL4435127 | 0.88 | F10 (0.32) | F10LMNAMAPK1KMT2A | |
| SCHEMBL8509610 | 0.87 | F10 (0.47) | F10LMNAMAPK1KMT2AF2 | |
| SCHEMBL3306401 | 0.87 | F10 (0.47) | F10LMNAMAPK1KMT2AF2 | |
| SCHEMBL13395166 | 0.86 | F10 (0.41) | F10F2F11 | |
| SCHEMBL3307604 | 0.86 | F10 (0.41) | F10F2F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309542-B2 | Substituted pyrrolidine amides, the production thereof, and the use thereof as medications | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-13 | — | — | US | disclosed |
| US-20100099664-A1 | SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099664-A1 | SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS | DDC, GLS, UROD | F10 2924/4885LMNA 3711/4885MAPK1 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.